EGFRVIII ACTIVATES A DISTINCT PATHWAY THAN WILD-TYPE EGFR BUT THE FINAL DECISION BELONGS TO WILD-TYPE EGFR

被引：0

作者：

Treda, Cezary ^{[1
]}

Stoczynska-Fidelus, Ewelina ^{[1
]}

Piaskowski, Sylwester ^{[1
]}

Grzela, Dawid ^{[1
]}

Zieba, Jolanta ^{[1
]}

Walczak, Maciej ^{[1
]}

Banaszczyk, Mateusz ^{[1
]}

Peciak, Joanna ^{[1
]}

Rieske, Piotr ^{[1
]}

机构：

[1] Celther Polska Sp Zoo, Lodz, Poland

来源：

ANTICANCER RESEARCH | 2014年 / 34卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

658

引用

下载

页码：6216 / 6217

页数：2

共 50 条

[41] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
Garcia-Saenz, Jose A.
Sastre, Javier
Diaz-Rubio Garcia, Eduardo
CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11): : 737 - 747
[42] Spontaneous Transformation from EGFR and ALK Wild-Type Lung Adenocarcinoma to Neuroendocrine Carcinoma
Kage, Hidenori
Kohsaka, Shinji
Shinozaki-Ushiku, Aya
Ushiku, Tetsuo
Takai, Daiya
Nakajima, Jun
Miyagawa, Kiyoshi
Aburatani, Hiroyuki
Mano, Hiroyuki
Nagase, Takahide
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : E126 - E128
[43] EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis
Krishna M. Talasila
Anke Soentgerath
Philipp Euskirchen
Gro V. Rosland
Jian Wang
Peter C. Huszthy
Lars Prestegarden
Kai Ove Skaftnesmo
Per Øystein Sakariassen
Eskil Eskilsson
Daniel Stieber
Olivier Keunen
Narve Brekka
Ingrid Moen
Janice M. Nigro
Olav K. Vintermyr
Morten Lund-Johansen
Simone Niclou
Sverre J. Mørk
Per Øyvind Enger
Rolf Bjerkvig
Hrvoje Miletic
Acta Neuropathologica, 2013, 125 : 683 - 698
[44] Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression
Rivera-Soto, Ricardo
Henley, Benjamin
Pulgar, Marian A.
Lehman, Stacey L.
Gupta, Himanshu
Perez-Vale, Kia Z.
Weindorfer, Megan
Vijayaraghavan, Smruthi
Yao, Tsun-Wen Sheena
Laquerre, Sylvie
Moores, Sheri L.
NPJ PRECISION ONCOLOGY, 2024, 8 (01)
[45] EGFR WILD-TYPE AMPLIFICATION AND ACTIVATION PROMOTE INVASION AND DEVELOPMENT OF GLIOBLASTOMA INDEPENDENT OF ANGIOGENESIS
Talasila, Krishna M.
Soentgerath, Anke
Euskirchen, Philipp
Rosland, Gro V.
Wang, Jian
Huszthy, Peter C.
Prestegarden, Lars
Skaftnesmo, Kai Ove
Sakariassen, Per Oystein
Eskilsson, Eskil
Stieber, Daniel
Keunen, Olivier
Nigro, Janice
Vintermyr, Olav K.
Lund-Johansen, Morten
Niclou, Simone P.
Mork, Sverre
Enger, Per Oyvind
Bjerkvig, Rolf
Miletic, Hrvoje
NEURO-ONCOLOGY, 2013, 15 : 6 - 6
[46] The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR
Mohyeldin, Mohamed M.
Akl, Mohamed R.
Siddique, Abu Bakar
Hassan, Hossam M.
El Sayed, Khalid. A.
BIOCHEMICAL PHARMACOLOGY, 2017, 126 : 51 - 68
[47] Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma
Luo, Jia-Wei
Guo, Yan-Hua
Wu, Feng-Ying
Li, Xue-Fei
Sun, Xue-Cheng
Wang, Jia-Lu
Zhou, Cai-Cun
DISEASE MARKERS, 2021, 2021
[48] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
Jose A. García-Sáenz
Javier Sastre
Eduardo Díaz-Rubio García
Clinical and Translational Oncology, 2009, 11 : 737 - 747
[49] EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis
Talasila, Krishna M.
Soentgerath, Anke
Euskirchen, Philipp
Rosland, Gro V.
Wang, Jian
Huszthy, Peter C.
Prestegarden, Lars
Skaftnesmo, Kai Ove
Sakariassen, Per Oystein
Eskilsson, Eskil
Stieber, Daniel
Keunen, Olivier
Brekka, Narve
Moen, Ingrid
Nigro, Janice M.
Vintermyr, Olav K.
Lund-Johansen, Morten
Niclou, Simone
Mork, Sverre J.
Enger, Per Oyvind
Bjerkvig, Rolf
Miletic, Hrvoje
ACTA NEUROPATHOLOGICA, 2013, 125 (05) : 683 - 698
[50] The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
Kaye, Brandon
Ali, Assad
Santiago, Raphael Augusto Correa Bastianon
Ibrahim, Bilal
Isidor, Julio
Awad, Hany
Sabahi, Mohammadmahdi
Obrzut, Michal
Adada, Badih
Ranjan, Surabhi
Borghei-Razavi, Hamid
CURRENT ONCOLOGY, 2023, 30 (05) : 4946 - 4956

← 1 2 3 4 5 →